

Carelink partners with Fujifilm to deploy COVID-19 drug in China

23 October 2020 | News

FUJIFILM Toyama Chemical will develop an injectable form of Avigan jointly with Carelink



FUJIFILM Toyama Chemical, based in Japan, has partnered with Chinese pharmaceutical company Carelink Pharmaceutical in deploying anti-influenza drug Avigan[®] Tablets in China.

Going forward, through a future application and approval of Avigan for imported drug registration, to be submitted by Carelink, FUJIFILM Toyama Chemical aims to introduce Avigan to the Chinese market.

Carelink is a pharmaceutical company that is actively engaged in developing new drugs by making use of their staff that have ample global experiences in Japan, Asia, Europe and the U.S., as well as extensive clinical development expertise and track records, with the aim of broadly supplying high-quality pharmaceuticals not only in China but to the entire world.

At present, Carelink has expanded its area of development to infectious diseases as well as lifestyle diseases, and is working to develop antiviral drugs. In addition, with pharmaceuticals that have already been approved in Europe and the U.S., the company collaborates with partner corporations both inside and outside China to promote clinical drug development and submit applications for their approval as imported drugs.

Furthermore, to expand therapeutic options using Avigan, FUJIFILM Toyama Chemical will develop an injectable form of Avigan jointly with Carelink.